Pre-Prints
- “Characterisation of DMPK and MBNL1 expression in cell models of Myotonic Dystrophy: A platform for drug screening” A Lopez-Martinez, S Martin-Gonzalez, N Torres-Conde, N Alcala-Manso, A Al-Ani, A Lopez de Munain, A Bigot, K Mamchaoui, G Nogales-Gadea, V Arechavala-Gomeza. February 2025 PrePrint BioRxiv. Now published in NAR Molecular Medicine
- “Collablots: Quantification of collagen VI levels and its structural disorganisation in cell cultures from patients with collagen VI-related dystrophies” N Osegui-Barcenilla, M Sendino, S Martín-González, I Gómez-Moro, A Benito-Agustino, N Torres-Conde, A López-Martínez, C Jimenez-Mallebrera, A Lopez-Marquez, V Arechavala-Gomeza. December 2024 PrePrint BioRxiv. Now published in Neuropathology and Applied Neurobiology.
- “Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model” J Poyatos-Garcia, P Soblechero-Martin, A Liquori, A Lopez-Martinez, E Gonzalez-Romero, RP Vazquez-Manrique, N Muelas, G Garcia-Garcia, J Ohana, V Arechavala-Gomeza, JJ Vilchez. Sept 2023 Preprint BioRxiv. Now published in Skeletal Muscle.
Book: Antisense RNA Design, Delivery, and Analysis
Editors: Virginia Arechavala-Gomeza, Alejandro Garanto
This open access volume gathers a variety of models, delivery systems, and approaches that can be used to assess RNA technology for exploiting antisense as a therapeutic intervention. Beginning with a section on the design of antisense technology and their delivery, the book continues by covering model systems developed to evaluate efficacy, both in vivo and in vitro, as well as methods to evaluate preclinically the toxicity associated with these new potential drugs, and intellectual property considerations. Chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
This book was conceived thanks to the network DARTER (Delivery of Antisense RNA Therapeutics). DARTER is funded by the EU Cooperation of Science and Technology (COST), which aims to enhance interaction and collaborations between researchers in Europe and other countries.
Access to the book ➡️ Antisense RNA Design, Delivery, and Analysis
Written Contributions
- Nov 2021. López-Martínez and Arechavala-Gomeza. Article describing COST Action “DARTER” in the journal of the Spanish Biochemistry and Molecular Biology Society. Here.
- Oct 2018. Soblechero-Martín and Arechavala-Gomeza, “Cómo mejorar la distribución de los medicamentos antisentido para acelerar su tránsito a la clínica”. Here
- Oct 2016 Fundación para el Conocimiento madri+d on the development of therapies for rare diseases (spanish) here.
- DMD research overwiew translation into spanish (updated late 2015). Click here for pdf.